NT5E and prostate carcinoma: These results appear in line with the data that indicate that the siRNA-mediated silencing of EpCAM and CD73 enhances sensitivity to chemotherapeutic agents and ionizing radiation in breast, pancreatic, and prostate cancer cells [35,43,44,45].